Navigation Links
Medication does not lower risk of fungal infection, death among ELBW infants
Date:5/3/2014

Use of the antifungal medication fluconazole for six weeks for extremely low birth-weight infants did not significantly reduce the risk of death or invasive candidiasis, a serious infection that occurs when candida (a type of fungus) enters the bloodstream and spreads through the body, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Invasive candidiasis is an important cause of infection in premature infants; despite treatment with antifungal therapy, invasive candidiasis has serious effects on premature infants, including severe neurodevelopmental impairment and death. Current recommendations include the use of fluconazole for prevention of this infection for infants with a birth weight of less than 1,000 grams (2.2 lbs.) who receive care in neonatal intensive care units (NICUs). However, most NICUs in the United States and the European Union have not uniformly adopted preventive use of fluconazole, based on controversies regarding high-risk patients, resistance, and safety, according to background information in the article.

Daniel K. Benjamin Jr., M.D., Ph.D., of Duke University, Durham, N.C., and colleagues evaluated the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low birth-weight infants (weighing less than 750 grams [1.7 lbs.] at birth). The study included 361 infants from 32 NICUs in the United States who were randomly assigned to receive either fluconazole (6mg/kg of body weight) or placebo twice weekly for 42 days.

The primary composite end point of death or invasive candidiasis by study day 49 was not statistically different between the 2 groups (fluconazole, 16 percent vs placebo, 21 percent). The percentage of infants who died prior to study day 49 was not different between the groups (14 percent vs 14 percent). Fewer infants developed definite or probable invasive candidiasis in the fluconazole (3 percent) vs in the placebo group (9 percent).

"Fluconazole prophylaxis compared with placebo was not associated with a statistically significant difference in the composite primary end pointdeath or definite or probable invasive candidiasis although it was associated with a statistically significant reduction in the incidence of definite or probable candidiasis alone. This study adds new evidence regarding the efficacy of fluconazole prophylaxis, but raises the question of whether prevention of invasive candidiasis translates into substantial improvements in the outcomes of prematurity."

"Based on both the results of our study in NICUs with a low incidence of invasive candidiasis, and previous prophylaxis trials in high-incidence NICUs, the routine use of fluconazole prophylaxis should be limited to units with moderate-to-high incidence of invasive candidiasis. However, additional research is needed to precisely define the incidence at which the benefits of fluconazole prophylaxis outweigh the risks," the authors write.


'/>"/>

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Nearly 50 percent of M.D.s believe diversion of ADHD stimulant medications among teens is a problem
2. UH Rainbow to study African-Americans response to asthma medications
3. HHS leaders call for expanded use of medications to combat opioid overdose epidemic
4. Medication does not help prevent ED following radiation therapy for prostate cancer
5. Medication does not reduce risk of recurrent CV events among patients with diabetes
6. Erectile dysfunction can be reversed without medication
7. Electronic medication alerts designed with provider in mind reduce prescribing errors
8. One in 5 older Americans take medications that work against each other
9. Anti-psychotic medications offer new hope in the battle against glioblastoma
10. Blood pressure medications given right after stroke not beneficial, study finds
11. MIT robot may accelerate trials for stroke medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual conference ... May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... science and clinical practice of radiosurgery, is recognizing five medical residents and students ... and stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, on ... penis transplant in the United States . The 64-year-old patient who received the transplant ... transplant could restore not only a natural appearance, but also urinary and sexual function ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, the consumer ... will deliver a new series of Q&A videos to clinicians and patients at ... expertise of Harvard Medical School faculty into brief videos that clinicians using vidscrip ...
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a pain ... A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated if ... spine surgeon at Atlantic Spine Center . , So named because of ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... According to the 2016 home healthcare ... for affordable healthcare solutions as since the early 2000s, the ... countries like the US, the healthcare cost rose faster than ... price index inflation rate stood at an average of 2.04% ... 3.62% during the same time period. This can be attributed ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented in ...   The conclusions of the study point to ... with 90% of the m presenting duration ... percent of the patients had clinical benefit.   ... I study of plitidepsin in combination with bortezomib and dexamethasone in patients with ...
Breaking Medicine Technology: